Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016 (European Urology)
We read with great interest the study by Kettunen et al. [1] on the conditional reprogramming (CR) method for generating patient-derived bladder cancer (BC) cell cultures and their feasibility for planning personalized treatment strategies.